Chris Chapman, our post-doctoral researcher leading a cutting-edge project to improve localised drug release in hard-to-treat cancers through the use of conducting polymers, has won a Rosetrees Entreprise Fellowship for his proposal titled “Medical implant to deliver precision cancer treatment through targeted chemotherapeutic delivery”.
Despite overall survival rates for cancers doubling in the last 40 years, many hard-to-treat cancers such as brain and pancreatic cancer are just as lethal today as they were a few decades ago. These cancers are difficult to treat due to the challenge of releasing enough chemotherapeutic drugs within the tumour without affecting the healthy tissue surrounding it. By using ionic drug delivery coupled with conducting polymers, Chris and his team will create an innovative device capable of releasing high amounts of chemotherapeutic drugs directly into the tumour with minimal impact on the tissue around it.
This fellowship will allow Chris to go above and beyond his current project and develop breakthrough technologies to improve both patient quality of life during treatment and survival rates for hard-to-treat cancers.